Construction method of viral deafness mouse model
By locally injecting a small amount of virus into the round window membrane of the mouse cochlea, the high mortality rate and unstable model formation of viral deafness mouse models in existing technologies have been solved, achieving high survival rate and high model formation rate in simulating pathological features, and providing an ideal experimental platform.
Patent Information
- Application Number
- CN202610165055.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-02-05
- Publication Date
- 2026-03-10
Smart Images

Figure CN121622748A_ABST
Abstract
Description
TECHNICAL FIELD
[0001] The present application relates to the technical field of animal model construction, and particularly relates to a construction method of a viral deafness mouse model. BACKGROUND
[0002] Congenital sensorineural hearing loss is one of the main diseases leading to hearing impairment in children, which seriously affects the language development and social interaction ability of children. Among the many pathogenic factors, congenital human cytomegalovirus (HCMV) infection is the primary cause of non-hereditary congenital hearing loss. According to statistics, HCMV infection leading to sensorineural hearing loss has the characteristics of progressive aggravation and delayed onset, and the pathogenic mechanism has not been fully elucidated, and there is currently a lack of effective treatment in the clinic.
[0003] In order to further study the pathological mechanism of CMV deafness and screen effective treatment drugs, it is crucial to construct a stable and reliable animal model. Because HCMV has strict species specificity, it cannot directly infect other animals, so researchers often use murine cytomegalovirus (MCMV) to infect mice to simulate congenital CMV infection in humans.
[0004] However, the existing construction method of MCMV infected deafness mouse model has obvious defects. The current mainstream modeling method mostly uses systemic infection routes, such as intraperitoneal injection or intracerebral injection. These methods mainly have the following two technical problems: First, the mortality rate is extremely high. In order to simulate congenital infection, it is usually necessary to select newborn mice (such as 0-3 days after birth) for virus inoculation. Because the immune system of newborn mice has not yet developed perfectly, systemic administration of high titer virus can easily cause severe systemic inflammatory response, leading to encephalitis, hepatitis, pneumonia and multiple organ failure, resulting in a large number of mice dying before hearing test, which greatly limits the sustainability of the experiment.
[0005] Second, the modeling rate is low and unstable. The inner ear has a special blood-labyrinth barrier, which can effectively block the virus in the blood circulation from entering the cochlear lymph. When using systemic administration route, the virus is difficult to break through the barrier and enter the inner ear, or the amount of virus entering the inner ear is not enough to cause significant hearing loss. This leads to a large individual difference in the same group of experimental animals, some of which show deafness, and some of which have normal hearing, and the uniformity and repeatability of the model are poor.
[0006] Therefore, it is urgent to develop a viral deaf mouse model construction method which can effectively avoid the blood-labyrinth barrier, precisely deliver viruses to the inner ear, avoid systemic damage, and improve the survival rate of animals. SUMMARY
[0007] In order to solve the problems in the prior art, the present application provides a viral deaf mouse model construction method, which uses a round window membrane local micro-injection technology to effectively break through the blood-labyrinth barrier, overcoming the technical difficulties of high mortality and unstable modeling of traditional systemic infection models. The model constructed by this method has the significant advantages of high survival rate, high modeling rate, and stable phenotype, precisely simulating the pathological characteristics of human viral deafness, and providing a standardized ideal experimental platform for deafness mechanism research and drug screening.
[0008] In order to achieve the above-mentioned purpose, the present application adopts the following technical solutions: The present application claims a viral deaf mouse model construction method, comprising the following steps: (1) Anesthetizing the mouse, cutting the skin behind the ear and separating the subcutaneous tissue to expose the mouse otocyst; (2) Preparing an opening on the otocyst to expose the cochlear round window; (3) Injecting a virus-containing solution through the round window membrane of the round window into the perilymph of the cochlea; (4) Closing the surgical area; Wherein, the virus is selected from viruses that can infect mice and cause hearing loss.
[0009] Preferably, in step (1), the specific operation of exposing the mouse otocyst includes blunt dissection at the intersection of the masseter muscle and the sternohyoid muscle, and the deep part of the sternohyoid muscle until the otocyst is touched. Using this dissection path can avoid important structures such as the facial nerve and quickly locate the otocyst.
[0010] Preferably, in step (1), the incision for cutting the skin behind the ear starts from the tip of the external ear and is parallel to the posterior margin of the mouse pinna with a distance of 0.3-0.8 mm from the posterior margin of the pinna.
[0011] Preferably, in step (3), the virus is mouse cytomegalovirus.
[0012] Preferably, in step (3), the injection volume of the virus-containing solution is 0.5-2.0 μL; the titer of the virus is 1×10 2 ~1×10 3 pfu / μL.
[0013] More preferably, the injection volume of the virus-containing solution is 1 μL; the titer of the virus is 400 pfu / μL.
[0014] Preferably, in step (3), the injection is performed using a microsyringe, and the needle of the microsyringe is selected from a 34G injection needle or a glass electrode with a lengthened tip; preferably, the glass electrode has a lengthened tip of about 0.5 mm, so as to reduce physical damage to the round window membrane.
[0015] Preferably, the mouse is a newborn mouse of 0-5 days after birth. The injection is performed within the time window, so as to ensure effective infection of the developing cochlea by the virus and ensure the surgical tolerance of the mouse.
[0016] More preferably, the mouse is a mouse of 3 days after birth.
[0017] Preferably, after step (4), the method further comprises a step of detecting the hearing threshold of the constructed model or performing cochlear tissue immunofluorescence detection to verify the success of the modeling.
[0018] Compared with the prior art, the method has the following beneficial effects: The existing construction method usually adopts a systemic infection route such as intraperitoneal injection, intracerebroventricular injection or nasal inhalation. Since the immune system of a newborn mouse has not yet developed perfectly, systemic viral infection easily leads to encephalitis, hepatitis or multiple organ failure, so that the mouse dies in large quantities in the early modeling stage. The method delivers the virus directly into the perilymph of the cochlea by using a local micro-injection mode through the round window membrane. The local administration mode greatly limits the spread of the virus to the whole body, avoids serious systemic inflammatory response and non-target organ damage, and thus significantly improves the survival rate of the mouse after the operation, thereby providing a guarantee for subsequent long-term hearing monitoring and experimental research.
[0019] Since there is a blood-labyrinth barrier in the cochlea, it is difficult to ensure that a sufficient amount of virus enters the inner ear by using a systemic administration mode, so that there is a large difference in modeling effect among individuals, and the conditions of “not being infected” or “not having obvious hearing loss” often occur. The method breaks through the physiological barrier by puncturing the round window membrane, and realizes direct contact between the virus and the cochlea tissue. Experimental results (ABR detection) show that the hearing threshold of the mouse model constructed by using the method is significantly increased at low, medium and high frequencies, and presents the characteristics of severe and stable sensorineural hearing loss, and the modeling rate is extremely high.
[0020] The method preferably uses a mouse of 0-5 days after birth, and cooperates with a specific anatomical path (intersection of masseter muscle and sternohyoid muscle) and micro-injection parameters. The surgical path avoids important structures such as the facial nerve, and cooperates with the puncture of the glass electrode or the micro-needle, so that the physical damage to the round window membrane and the surrounding bone is extremely small. The mouse recovers quickly after the operation, and the control group experiment shows that the operation itself does not cause hearing loss, thereby ensuring the reliability of the experimental results. BRIEF DESCRIPTION OF DRAWINGS
[0021] In order to more clearly illustrate the technical solutions of the embodiments of the present application, the following will briefly introduce the drawings needed to be used in the embodiments. It should be understood that the following drawings only show some embodiment schematic diagrams of the present application, and therefore should not be regarded as a limitation to the scope. For those skilled in the art, other related drawings can also be obtained without creative labor under the premise of the drawings.
[0022] Figure 1 Schematic diagram of the surgical method for injecting virus into the round window membrane of mouse cochlea; Figure 2 Detection results of ABR hearing threshold of mice infected with virus; Figure 3 Green fluorescent protein expressed by mouse cytomegalovirus in the cochlea of the mouse after modeling. DETAILED DESCRIPTION
[0023] In order to make the purpose, technical solutions and advantages of the present application more clear, the following will further describe the present application with embodiments. Of course, the specific embodiments described here are only used to explain the present application, and are not used to limit the present application.
[0024] Unless otherwise specified, the chemical reagents and materials in the present application are purchased through market channels or synthesized by raw materials purchased through market channels.
[0025] A method for constructing a viral deafness mouse model, comprising the following steps: (1) Anesthetize a newborn mouse of 0-5 days after birth, incise the skin behind the ear and separate the subcutaneous tissue, and the incision of the skin behind the ear starts from the tip of the external ear and is parallel to and 0.3-0.8 mm away from the posterior edge of the mouse ear; bluntly separate at the intersection of the masseter muscle and the sternohyoid muscle, and the deep part of the lower edge of the sternohyoid muscle, until the auditory vesicle is touched.
[0026] (2) Prepare an opening on the auditory vesicle to expose the round window of the cochlea; (3) Inject a virus-containing solution into the perilymph of the cochlea through the puncture of the round window membrane of the round window; the virus is selected from viruses capable of infecting mice and causing hearing loss; the injection volume of the virus-containing solution is 0.5-2.0 μL; the titer of the virus is 1×10 2 ~1×10 3 pfu / μL; a microsyringe is used for injection, and the needle of the microsyringe is selected from a 34G injection needle or a glass electrode with a lengthened tip; (4) Seal the surgical area.
[0027] The present application will be further described by specific embodiments.
[0028] Main reagents and materials: 1. Experimental animals: C57BL / 6 mice, SPF level, purchased from Spafas (Beijing) Biotechnology Co., Ltd.
[0029] 2. Virus: Recombinant mouse cytomegalovirus (MCMV) expressing green fluorescent protein (EGFP), titer 400 pfu / μL.
[0030] 3. Main instruments: TDT auditory physiology workstation (Tucker-Davis Technologies, USA), laser confocal microscope (Zeiss), microsyringe pump, glass microelectrode puller.
[0031] Example 1: Construction of viral deafness mouse model by round window membrane injection This example provides a method for constructing a sensorineural deafness model by microinjection of virus through the round window pathway, and the specific operation steps are as follows: 1. Animal preparation and anesthesia Select postnatal day 3 (P3) neonatal C57BL / 6 mice as experimental objects. Prepare 1.25% trichloroethanol solution as anesthetic, and inject intraperitoneally at a dose of 0.1 mL / 10 g body weight. After the mouse loses the righting reflex, breathes evenly, and does not respond to pain stimuli, it is fixed on a constant temperature operating table in a lateral position to prevent hypothermia during the operation.
[0032] 2. Expose the auditory bulla Under the assistance of a stereomicroscope, the skin behind the right ear of the mouse is prepared, and iodophor and 75% ethanol are used alternately for disinfection.
[0033] Make a cut about 1.0 cm long behind the ear, with the starting point at the tip of the external ear and the running direction parallel to the posterior margin of the mouse's ear, about 0.5 mm away from the posterior margin of the ear. After cutting the skin and subcutaneous tissue, the deep muscle is exposed.
[0034] Identify the junction of the masseter muscle and the sternohyoid muscle, and use it as a landmark to bluntly separate along the deep part of the sternohyoid muscle. Be careful to avoid the facial nerve and blood vessels during the separation process. Bluntly separate until the bony structure, the auditory bulla, is touched.
[0035] 3. Round window injection Clean the soft tissue on the surface of the auditory bulla. Use a sharp dissection needle to gently pick up a small hole behind the wall of the auditory bulla to prepare a surgical window. Through this window, adjust the focus of the microscope to clearly observe the cochlear basal turn and the round window located below it.
[0036] Use a glass microelectrode puller to prepare a glass electrode with an appropriate tip diameter (or directly use a 34G microsyringe needle), connect it to a microsyringe system, and draw MCMV virus solution with a titer of 400 pfu / μL.
[0037] Adjust the micro-manipulator so that the tip of the needle is perpendicular to the round window membrane and into the perilymphatic space. Start the micro-syringe pump and slowly inject 1.0 μL of virus solution into the perilymphatic fluid of the cochlea.
[0038] After injection, keep the needle in place for a few minutes, and then slowly pull out the needle after the endolymphatic pressure is balanced and the tissue retracts to seal the needle hole.
[0039] 4. Post-operative treatment After confirming that there is no liquid leakage at the round window, reset the muscles and skin, and suture the incision. Disinfect the wound again, and place the mouse on the recovery table for warming, and then put it back into the mother cage after it wakes up.
[0040] Control group treatment: Another group of C57BL / 6 mice of the same age (P3) were treated using the same surgical path and injection parameters as described above, but the injection was replaced with an equal volume (1.0 μL) of sterile saline.
[0041] Example 2: Verification of the model hearing function (ABR detection) On the 18th day after birth (P18), the auditory brainstem response (ABR) of the mice in the MCMV infection group and the control group constructed in Example 1 was detected to evaluate the hearing loss.
[0042] 1. Detection method The mouse was anesthetized with 1.25% tri-bromoethanol and placed in a soundproof shielded room. The subcutaneous needle electrode was recorded as follows: the recording electrode was placed on the top of the head, the reference electrode was placed on the ipsilateral postauricular mastoid, and the ground electrode was placed on the back.
[0043] The sound signal was generated by the TDT auditory physiology workstation and introduced into the mouse's external auditory canal through a high-frequency loudspeaker.
[0044] The stimulation sound signal includes: Click: used to evaluate overall hearing function.
[0045] Short pure tone: used to evaluate hearing at specific frequencies, and the frequency points covered 4 kHz, 8 kHz, 12 kHz, 16 kHz, 24 kHz, 32 kHz, and 40 kHz.
[0046] The stimulation intensity started from 90 dB SPL and decreased by 5 dB or 10 dB until no repeatable waveform could be induced. The minimum sound pressure level that could induce a waveform was recorded as the hearing threshold.
[0047] 2. Detection results The experimental results are shown (see the attached drawings of the specification Figure 2 ): Control group (saline group): ABR thresholds were within the normal range at all detection frequencies, indicating that the round window injection procedure itself did not cause significant damage to the hearing of mice.
[0048] Experimental group (MCMV group): Compared with the control group, MCMV-infected mice showed a significant increase in ABR threshold under Click stimulation and stimulation at all short pure audio frequencies from 4 kHz to 40 kHz. The threshold increase was particularly pronounced in the high-frequency region (16~32 kHz), showing characteristics of severe sensorineural hearing loss.
[0049] Statistical analysis showed that the difference in hearing threshold between the two groups was significant (P<0.05).
[0050] Example 3: Verification of viral infection status in the cochlea After hearing tests were completed (P18), the mice were immediately euthanized, and the distribution and infection status of the virus in the cochlea were verified by histological methods.
[0051] 1. Tissue sample preparation The mouse cochlea was removed by decapitation, and excess tissue was trimmed away. It was then fixed overnight in 4% paraformaldehyde (PFA).
[0052] The fixed cochlea was placed in a 10% EDTA decalcification solution and decalcified at room temperature for 48 hours.
[0053] After decalcification, the sample was dehydrated and settled with 30% sucrose, followed by embedding with OCT embedding medium. Sections were then prepared along the cochlear axis using a cryostat, with a section thickness of 10 μm.
[0054] Alternatively, after decalcification, the cochlear basilar membrane can be dissected directly under a microscope to prepare a cochlear lamella.
[0055] 2. Fluorescence observation Since the MCMV virus genome used in this embodiment has integrated the enhanced green fluorescent protein (EGFP) gene, after the sections or slides are washed with PBS and mounted, they can be directly observed without incubation with immunofluorescence antibodies.
[0056] The sample was observed using a laser confocal microscope.
[0057] 3. Observation Results The experimental results show (please refer to the instruction manual appendix) Figure 3 ): Bright green fluorescence (EGFP) was directly observed in the cochlear tissue of the experimental group mice. This confirms that the MCMV virus injected via the round window route effectively infects and replicates in multiple key cells within the cochlea, leading to corresponding pathological changes and hearing loss.
[0058] The above description is only a preferred embodiment of the present invention, but the scope of protection of the present invention is not limited thereto. Any equivalent substitutions or modifications made by those skilled in the art within the scope of the technology disclosed in the present invention, based on the technical solution and inventive concept of the present invention, should be covered within the scope of protection of the present invention.
Claims
1. A method for constructing a viral deafness mouse model, characterized by, The method comprises the following steps: (1) anesthetize the mouse, incise the skin behind the ear and separate the subcutaneous tissue to expose the mouse auditory bulla; (2) make an opening on the auditory bulla to expose the cochlea round window; (3) inject a virus-containing solution into the perilymph of the cochlea through the round window membrane of the round window; (4) close the surgical area; wherein the virus is selected from viruses capable of infecting mice and causing hearing loss.
2. The method of claim 1, wherein, In step (1), the specific operation of exposing the mouse auditory bulla comprises blunt dissection at the intersection of the masseter muscle and the sternodelidomastoid muscle, the deep part of the sternodelidomastoid muscle, until the auditory bulla is touched.
3. The method of claim 1, wherein, In step (1), the incision of the skin behind the ear starts from the tip of the external ear, is parallel to the posterior margin of the mouse pinna, and is 0.3-0.8 mm away from the posterior margin of the pinna.
4. The method of claim 1, wherein, In step (3), the virus is mouse cytomegalovirus.
5. The method of claim 1, wherein, In step (3), the injection volume of the virus-containing solution is 0.5-2.0 μL; the titer of the virus is 1 x 10 2 ~1 x 10 3 pfu / μL.
6. The method of claim 1, wherein, In step (3), the injection volume of the virus-containing solution is 1 μL; the titer of the virus is 400 pfu / μL.
7. The method of claim 1, wherein, In step (3), a microsyringe is used for injection, and the needle of the microsyringe is selected from a 34G injection needle or a glass electrode with a lengthened tip.
8. The method of claim 1, wherein, The mouse is a newborn mouse 0-5 days after birth.
9. The method of claim 1, wherein, The mouse is a mouse 3 days after birth.
10. The method of claim 1, wherein, After step (4), the method further comprises the step of detecting the hearing threshold or the cochlear tissue immunofluorescence of the constructed model to verify the success of the modeling.
Citation Information
Patent Citations
Application of retrograde recombinant adeno-associated virus type 2 in infected spiral neurons
CN110423778A
Construction method of sudden deafness mouse model characterized by inflammation
CN114788508A
Method of treating or preventing hearing loss
WO2011075838A1
